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Background: Bevacizumab, a monoclonal antibody against vascular endothelial
growth factor (VEGF)-A, has shown efficacy in patients with advanced non-
squamous non-small cell lung cancer (NSCLC). There are no identified or clini-
cally validated biomarkers to determine the efficacy of bevacizumab. In this
study, we assessed the adequacy of chemokine (C-X-C motif) ligand 16 (CXCL16)
as a biomarker for patients treated with bevacizumab-containing chemotherapy
regimen.
Methods: Patients diagnosed histologically with NSCLC were enrolled. Serial
serum CXCL16 levels during treatment were measured by enzyme-linked immu-
nosorbent assay. The relationship between serum CXCL16 levels before and after
treatment, progression-free survival, and overall survival were analyzed. CXCL16
and VEGF-A expressions in lung cancer tissue were also evaluated by immuno-
histochemical tests.
Results: The median serum level of CXCL16 in these patients was 3.4 ng/mL,
which was significantly higher than that in age-matched healthy adults (2.2
ng/mL). Immunohistochemistry results showed that CXCL16 was predominantly
localized in the tumor stroma, whereas VEGF was expressed in tumor cells.
Including bevacizumab with chemotherapy led to lower CXCL16 levels post-
chemotherapy, which correlated with better response rates. In addition, evalua-
tion of differences in serum CXCL16 levels before and after the first-line
chemotherapy showed that longer overall survival was achieved in patients who
showed a larger decrease in serum CXCL16 levels.
Conclusions: According to our findings, serum CXCL16 level was identified as a
potential biomarker for the efficacy of therapy, including anti-VEGF.
Key points
Significant findings of the study
Patients with NSCLC whose serum CXCL16 levels decreased below 0.07 ng/mL
after chemotherapy, showed longer overall survival than those without this
decrease. Moreover, low CXCL16 levels corresponded to better response rates
among patients with advanced NSCLC treated with bevacizumab-containing
chemotherapy.
What this study adds
Previously there were no identifiable predictive biomarkers to determine the effi-
cacy of bevacizumab. Data from our findings identified serum CXCL16 level as a
potential biomarker for the efficacy of bevacizumab-containing chemotherapy.
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Non-small cell lung cancer (NSCLC) accounts for 85%–
90% of all cases of lung cancer and patients with NSCLC
are often diagnosed in the advanced stages.1 Bevacizumab,
a monoclonal antibody against vascular endothelial growth
factor (VEGF)-A, has shown efficacy by inhibiting abnor-
mal vascular growth in malignant tumors when added to
the platinum-doublet first-line therapy for patients with
advanced nonsquamous NSCLC.2 Although several studies
have been conducted, none has identified or validated a
clinically applicable predictive biomarker for bevacizumab
efficacy for the treatment of NSCLC.3–7
The chemokine (C-X-C motif) ligand 16 (CXCL16) and its
receptor, C-X-C chemokine receptor (CXCR6), affect tumor
progression through different pathways, including leukocyte
recruitment and function, cellular senescence, tumor cell pro-
liferation, survival, invasion, and metastasis.8–12 It has been
reported that CXCL16 is critical for evaluating the prognosis
of several malignant tumors.13 CXCL16 is also recognized as a
hypoxic stress marker in the tumor microenvironment based
on its relationship with hypoxia-induced factor.14 It has also
been reported that hypoxic environments are closely associ-
ated with angiogenesis.15–17 Thus, these findings indicate the
possibility of CXCL16 reflecting the concentration of VEGF
and the efficacy of anti-VEGF therapy. However, little is
known about the effect of serum CXCL16 levels in lung can-
cer patients. In this article, serum CXCL16 levels in lung can-
cer patients and expression of CXCL16 in lung cancer
samples were examined to evaluate the clinical implications
for NSCLC patients.
Methods
Study design and patient samples
The expression of CXCL16 in tumor tissues and levels in sera
were assessed. Sera were collected from patients with NSCLC
at Yokohama City University from October 2010 to August
2016. The eligible patients were above 18 years and diagnosed
histologically as having NSCLC. They were classified by mul-
timodal approaches such as whole-body computed tomogra-
phy (CT), head magnetic resonance imaging (MRI), and/or
fluorine-18 fluorodeoxyglucose positron emission tomogra-
phy (FDG-PET), as being at an advanced stage of the disease
or having postoperative recurrence (The International Associ-
ation for the Study of Lung Cancer seventh edition of Tumor
Node Metastasis Staging classification), and they were cyto-
toxic agent-naïve. Sera from these patients were collected just
before the initiation of chemotherapy, before the next cycle,
and at the time of evaluation of the efficacy of chemotherapy
by imaging. Serum samples were separated from peripheral
venous blood and maintained at −80!C until analysis.
Collected data included demographic characteristics at the
time of the initiation of chemotherapy, disease stage at diag-
nosis, history of operation, the treatment regimen, the muta-
tional status of epidermal growth factor receptor (EGFR)/
echinoderm microtubule-associated protein-like 4 - anaplastic
lymphoma kinase (EML4-ALK), progression-free survival
(PFS; time from administration to disease progression), and
overall survival (OS; time from administration to death from
any cause). Tumor responses were assessed according to
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Patients’ characteristics are shown in Table 2.
Serum CXCL16 levels were measured as described
below. The relationship between the starting value and
change in the ratio of serum CXCL16 levels, therapeutic
effects, PFS, and OS were analyzed. After the measurement
of serum CXCL16 levels, patients with similar pretreatment
serum CXCL16 levels and similar changes in serum
CXCL16 levels post-treatment were assigned into two
groups. Data analysis was computed using GraphPad
Prism version 6 for Mac (GraphPad Software, San Diego).
The research was conducted per the 1964 Declaration of
Helsinki and amendments. This study was approved by the
institutional review board at Yokohama City University
(Approved No. B140703019). All participants gave written
informed consent before their inclusion in the study.
ELISA
The value of serum CXCL16 level was measured using
human CXCL16 ELISA kit (Human CXCL16 Quantikine
ELISA Kit, R&D Systems, Minneapolis, MN, USA), follow-
ing the manufacturer’s protocol, and all analyses were per-
formed in duplicates for the assessment of the interassay
variations. Briefly, to 100 μL of assay diluent (provided
with the kit), 50 μL of standards, controls, and serum sam-
ples were added in different wells of an ELISA plate and
incubated for 2 hours at room temperature. This was
followed by washing with quantikine wash buffer (provided
with the kit) four times. Then, 200 μL of conjugated anti-
body was added to each well, and the plate was further
incubated for 2 hours at room temperature, and the plate
was washed thereafter as described previously. Next,
200 μL of substrate solution was added, and the plate was
incubated for 30 minutes in the dark at room temperature.
After incubation, 50 μL of stop solution (2N H2SO4) was
added to each well, and the optical density was read using
a Multi-Detection Microplate Reader (Powerscan HT, DS
Pharma Biomedical, Osaka, Japan) at 450 nm.
Immunohistochemistry
Immunohistochemical analysis for the expression of
CXCL16 and VEGF-A was performed using lung cancer
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tissue microarray (US Biomax, Inc., Rockville, MD, USA).
All tissue samples were collected following appropriate eth-
ical standards, and in line with the Health Insurance Porta-
bility and Accountability Act approved protocol (USA).
Written informed consent was obtained from all donors.
The tissue microarray blocks were fixed with formalin and
cut into 5 μm thick sections and stained to check for the
presence of CXCL16 (mouse monoclonal, GTX632502, dilu-
tion 1:100, GeneTex, San Antonio, TX) and VEGF-A (rabbit
monoclonal, ab27620, prediluted, Abcam, UK) following the
manufacturer’s protocol. Endogenous peroxidase activity was
temporarily blocked after deparaffinization. Antigen retrieval
was accomplished using citric acid buffer at pH 6.0 in a heat-
resistant container at 121!C for 10 minutes. To minimize
nonspecific staining, slides were incubated with fetal goat
serum at 37!C for 15 minutes. After blocking, slides were
incubated with each of the primary antibodies against the
antigens mentioned above at 37!C for 1 hour. After the sec-
ond incubation with peroxidase linked antibody (rabbit poly-
clonal, 424 141, Nichirei Biosciences, Tokyo, Japan), substrate
chromogen was added, and the specimens were lightly coun-
terstained with hematoxylin. The expression levels of
CXCL16 and VEGF-A in cancer cells or stromal cells were
statistically compared using chi-square tests.
Statistical analysis
Fisher’s exact tests were conducted for the comparison of
CXCL16 and VEGF expression in lung cancer tissue array
and the comparison of the response rate between the low
and high CXCL16 groups. Statistical analyses of the differ-
ence in serum CXCL16 levels between healthy people and
NSCLC patients and the comparison of the pre- and post-
chemotherapy serum CXCL16 levels were conducted using
a two-sided student’s t-test. P-values <0.05 were considered
statistically significant. The Kaplan-Meier method was used
to analyze the PFS or OS among the high and low serum
CXCL16 groups. Log-rank tests were used to determine the
statistical significance in survival curves.
Results
CXCL16 was expressed in stromal cells at
the cancer site, whereas VEGF-A was
expressed in cancer cells
We assessed the expression of CXCL16 and VEGF-A and
conducted analysis using lung cancer tissue microarray
(US Biomax, Inc., Rockville, MD, USA). Differences in local-
ization between CXCL16 and VEGF-A expression were clar-
ified in the samples identified in lung cancer tissue array.
From the results, 86 and 16 tissue samples were detected for
the expression of CXCL16 and VEGF-A, respectively. The
expression of CXCL16 was dominant in the stromal cells,
whereas VEGF-A tended to be expressed more in the cancer
cells (Figure SS1). Thus, these markers were significantly dif-
ferent in expression patterns (Table 1).
Serum CXCL16 was significantly increased
in patients with NSCLC compared to that
in healthy volunteers
This study enrolled 40 patients with NSCLC. Patients’
characteristics are summarized in Table 2. The clinical
Table 1 CXCL16 and VEGF expression in lung cancer tissue array. Sta-







The expression levels of CXCL16 and VEGF in cancer cells
Cancer
cells
High 1 (1) 4 (25) 0.002
Low 36 (42) 7 (44)
None 49 (57) 5 (31)
The expression levels of CXCL16 and VEGF in stromal cells
Stromal
cells
High 18 (21) 0 (0) 0.002
Low 42 (49) 3 (19)
None 26 (30) 13 (81)
CXCL16, chemokine (C-X-C motif); VEGF, vascular endothelial growth
factor.
Table 2 Patient characteristics
Patient demographics (n = 40)
Age at diagnosis Median (range) 66.5 (38–85)
Sex Male 21 (52.5%)
Female 19 (47.5%)
Smoking Never 14 (35.0%)
Ever 18 (45.0%)
Current 8 (20.0%)
Stage IIIB 3 (7.5%)
IV 34 (85.0%)
Postoperative recurrence 3 (7.5%)
Histology Adenocarcinoma 34 (85.0%)
Squamous cell carcinoma 4 (10.0%)
NSCLC 1 (2.5%)
LCNEC 1 (2.5%)
PS 0 14 (35.0%)
1 12 (30.0%)
2 5 (12.5%)
Regimen Platinum doublets with BEV 13 (32.5%)
Platinum doublets 14 (35.0%)
EGFR-TKI 11 (27.5%)
ALK-TKI 2 (5.0%)
ALK, anaplastic lymphoma kinase; BEV, bevacizumab; EGFR, epidermal
growth factor receptor; LCNEC, large cell neuroendocrine carcinoma;
NSCLC, non-small cell lung cancer; PS, performance status; TKI, tyro-
sine kinase inhibitor.
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characteristics of the patients were as follows: the median
age was 66.5 (range: 38–85) years, the male/female ratio
was 21 (52.5%)/19 (47.5%), there were 34 adenocarcinomas
(85.0%), and the majority of the clinical stages were stage
IV with 34 cases (85.0%). Cytotoxic agents and tyrosine
kinase inhibitors (TKI) were received by 27 and 13 patients,
respectively. Of patients who received cytotoxic agent che-
motherapy, 14 received treatment with bevacizumab, and
13 patients received treatment without bevacizumab.
Serum CXCL16 levels in the 40 patients with NSCLC and
27 healthy volunteers were compared. Fig 1 shows the con-
centration of CXCL16 in serum detected by ELISA. The
median serum CXCL16 level before treatment in patients
with NSCLC was 3.5 (2.0–8.1) ng/mL, which was signifi-
cantly higher than that in age-matched healthy adults
(2.1 ng/mL, P < 0.05).
Serum CXCL16 was significantly decreased
after successful treatment with
bevacizumab
Fig 2 shows the difference in serum CXCL16 values pre-
and post-chemotherapy when patients were treated with or
without bevacizumab. Serum CXCL16 levels was signifi-
cantly decreased in patients showing stable disease, partial
response, or complete response after 2–4 courses of treat-
ment with platinum-doublet plus bevacizumab concurrently,
whereas CXCL16 levels did not decrease in patients treated
using platinum-doublet without bevacizumab (Fig 2). These
results indicate that serum CXCL16 levels may play an
important role in the efficacy of anti-VEGF therapy.
CXCL16 may predict the efficacy of
bevacizumab in addition to chemotherapy
To assess the predictive value of serum CXCL16 levels in
patients treated with anti-VEGF therapy, patients who
received bevacizumab in addition to chemotherapy were
assigned into two groups according to their serum CXCL16
concentrations (cutoff value was 3.45 ng/mL, Fig 3). The
response rate (RR) was significantly higher in the low
CXCL16 group (RR = 85.7%) than in the high CXCL16
group (RR = 16.5%) (P = 0.029, Table 3). However, there
were no significant differences in OS (Fig 3a) and PFS
(Fig 3b).
Significant decrease in CXCL16 after
chemotherapy is related to longer OS
among NSCLC patients
When OS in patients treated with chemotherapy was eval-
uated against the difference in CXCL16 levels pre- and
post-chemotherapy, it was observed that patients who
showed a significant decrease in CXCL16 levels after che-





















Figure 1 Comparison of serum CXCL16 between healthy volunteers
and non-small cell lung cancer patients (NSCLC). Comparison of serum
CXCL16 concentration between healthy volunteers (n = 27) and NSCLC
(n = 40). The lines indicate the median value for each group. The con-
centrations were statistically compared with the student t-test. CXCL16,



















With Bev     Without Bev
N.S.*
* P < 0.05
Pre PrePost Post
Figure 2 Changes in serum CXCL16 levels in
chemotherapy-sensitive patients between pre-
and post-treatment. (a) Serum CXCL16 levels
at pre- and post-chemotherapy, including
bevacizumab among patients who achieved
stable disease, partial response or complete
response after 2–4 courses of treatment
(n = 12). CXCL16 levels were significantly
decreased. (b) Serum CXCL16 levels among
those undergoing therapy without
bevacizumab (n = 12). *P < 0.05 (compared
with serum CXCL16 level before treatment).
Bev, bevacizumab; Chemo, chemotherapy;
CXCL16, chemokine (C-X-C motif ) ligand 16.
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showed a small decrease (cutoff value was 0.07 ng/mL,
Fig 4a). In the groups with large and small decrease in
CXCL16 levels, nine and three patients were treated with
cytotoxic agents and bevacizumab, respectively. Other
patients were treated with cytotoxic agents. These findings
were consistent with the analysis findings when squamous
cell lung cancer patients were excluded (Fig 4b). Hence,
pretreatment with serum CXCL16 and VEGF-A concentra-
tions had no significance as prognostic markers (data not
shown); a larger decrease in serum CXCL16 levels post-
chemotherapy may imply a better prognosis. These data
revealed the relationship between serum CXCL16 level and
chemotherapy with bevacizumab.
Discussion
VEGF is an important factor in cancer angiogenesis and is
upregulated by oncogene expression, various growth















































PFS between high and low CXCL16 groups
a
b
Figure 3 Overall survival and progression-free survival after chemother-
apy, including bevacizumab. (a) Comparison of overall survival
(OS) after chemotherapy, including bevacizumab based on low or high
CXCL16. ( ) CXCL 16 low (N = 7) mOS 1306 (days). ( ) CXCL
16 high (N = 7) mOS 380 (days). (b) Comparison of progression-free
survival (PFS) after chemotherapy, including bevacizumab based on low
or high CXCL16. ( ) CXCL 16 low (N = 12) mPFS 288 (days). ( )
CXCL 16 high (N = 12) mPFS 204 (days). OS and PFS were statistically
analyzed by the log-rank test. CXCL16, chemokine (C-X-C motif) ligand
16; mOS, median overall survival; mPFS, median progression-free sur-
vival; VEGF, vascular endothelial growth factor.
Table 3 The difference of response after treatment between CXCL16
low and high group





RR 85.7% 16.7% 0.029
DCR 85.7% 100% n/a
Statistical analysis was performed using the Fisher’s exact test. CR,
complete response; CXCL16, chemokine (C-X-C motif); DCR, disease
control rate; PD, progressive disease; PR, partial response; RR, response
rate; SD, stable disease.










































Figure 4 Overall survival based on the difference in CXCL16 after che-
motherapy. Overall survival (OS) for patients with large difference in
CXCL16 between pre- and post-chemotherapy versus those with low
difference. The cutoff value of the CXCL16 concentration was 0.07
ng/ml. Statistical comparison was done using the log-rank test.
CXCL16, chemokine (C-X-C motif) ligand 16. ( ) large decrease
(N = 12) mOS 453 (days) ( ) small decrease (N = 12) mOS 291 (days).
( ) large decrease (N = 10) mOS 411 (days) ( ) small decrease
(N = 9) mOS 274 (days).
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factors, and hypoxia. VEGF targeted therapy, including
bevacizumab, which is the humanized antibody for VEGF-
A, offers clinical benefits to patients with several types of
cancer including colon cancer, breast cancer, and NSCLC.
This is because it prevents angiogenesis in tumors thereby
halting the development and growth of these cancers.2,17,18
CXCL16 is a chemokine that belongs to one of the CXC
chemokine families and is usually produced by dendritic
cells. In the tumor microenvironment, the CXCL16 and
CXCR6 axes enhance tumor progression through the regu-
lation of proangiogenic factor expression with the
AKT/mTOR pathway in prostate cancer,19 the enhance-
ment of precancerous inflammation in hepatocellular
carcinoma,20 and the promotion of cell migration by
hypoxia-induced factor 1 alpha (HIF-1α) in breast cancer.21
The mechanism of proliferation and migration of cancer
cells suggests that CXCL16 induces angiogenesis in an
autocrine manner via ERK, Akt, and p38 pathways, and
VEGF secretion by HIF-1α modulation.22 Our data rev-
ealed that serum CXCL16 levels increased among patients
with NSCLC (Fig 1), and its location of expression was dif-
ferent from that of VEGF, which is more likely to be seen
at the cancer site as previously reported (Table 3).14 More-
over, based on the results showing an association between
decreases in CXCL16 levels and improvement of prognosis,
serum CXCL16 level was identified as a potential bio-
marker for the chemotherapy efficacy, especially anti-
VEGF therapy (Fig 4).
It was reported that serum CXCL16 levels were elevated
in patients with prostate cancer23 or pancreatic cancer24
than in those in healthy control patients. Recent data indi-
cated that CXCL16 was also upregulated in the case of
NSCLC (Fig 1). This is the first report evaluating the
changes in serum CXCL16 levels pre- and post-
chemotherapy in patients with NSCLC. Interestingly, a
larger difference in serum CXCL16 was related to longer
survival. Several studies have been performed to detect pre-
dictive biomarkers for anti-VEGF therapy efficacy, but at
the moment, none have proven to have clinical benefits in
the treatment of patients with advanced lung cancer. Our
data highlights the possibility that serum CXCL16 levels
can be monitored to estimate the treatment efficacy of
anti-VEGF therapy in the future.
The current study has several limitations. This was a
single-center based study with a small number of patients,
who are only Japanese. Second, treatments were chosen by
the principal physician. To overcome these limitations,
multicenter international randomized trials should be con-
ducted to evaluate the utility of serum CXCL16 levels as a
biomarker to predict the efficacy of chemotherapy with the
inclusion of anti-VEGF treatment.
In conclusion, our data suggested that serum CXCL16
levels can be identified as a potential biomarker for the
efficacy of chemotherapies, such as bevacizumab and other
anti-VEGF therapies for patients with advanced NSCLC.
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Supporting Information
Additional Supporting Informationmay be found in the online
version of this article at the publisher’s website:
Figure S1 Differences in the expression between VEGF-A and
CXCL16 in non-small cell lung cancer patients by
immunohistochemistry. Immunohistochemical analysis of the
expression of VEGF-A and CXCL16 was evaluated using lung
cancer tissue microarray (US Biomax, Inc., Rockville, MD,
USA). CXCL16 was expressed in both stromal and cancer cells,
whereas VEGF tended to be expressed in cancer cells.
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